

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Singular Health Group Limited
<b>ABN</b>	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Thomas Hanly
<b>Date of last notice</b>	4 January 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect Securities held by Sylvan Capital Pte Ltd – an entity controlled by Mr Hanly, and of which he is a beneficiary.
<b>Date of change</b>	7 December 2022, 9 December 2022
<b>No. of securities held prior to change</b>	<div>Direct</div> <div>(i) 1 fully paid ordinary share – escrowed to 12 February 2023</div> <div>(ii) 1,500,000 Class A Performance Rights – escrowed to 12 February 2023</div> <div>(iii) 1,500,000 Class B Performance Rights – escrowed to 12 February 2023</div> <div>(iv) 6,000,000 Unlisted Options (\$0.30, 10 February 2025), escrowed to 12 February 2023</div> <div>(v) 16,064 fully paid ordinary shares</div> <div>Indirect</div> <div>i) 100,000 fully paid ordinary shares</div> <div>ii) 3,400,000 fully paid ordinary shares – escrowed to 12 February 2023</div>
<b>Class</b>	Fully paid ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	Direct i) 19,926  Indirect i) Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$2,690.02
<b>No. of securities held after change</b>	Direct (i) 1 fully paid ordinary share – escrowed to 12 February 2023 (ii) 1,500,000 Class A Performance Rights – escrowed to 12 February 2023 (iii) 1,500,000 Class B Performance Rights – escrowed to 12 February 2023 (iv) 6,000,000 Unlisted Options (\$0.30, 10 February 2025), escrowed to 12 February 2023 (v) 35,990 fully paid ordinary shares  Indirect (i) 100,000 fully paid ordinary shares (ii) 3,400,000 fully paid ordinary shares – escrowed to 12 February 2023
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---

<sup>+</sup> See chapter 19 for defined terms.